Clinical Advances and Therapeutic Challenges in Small-Cell Lung Cancer and Rare Thoracic Cancers

Dear Colleagues,

The clinical decision-making process for patients with rare tumors poses a significant challenge in oncology, particularly in defining individualized therapeutic strategies.

Unlike common malignancies, the available evidence and literature on rare tumors are predominantly limited to case series, retrospective studies, and small phase II prospective trials. Randomized trials, which are usually the cornerstone of therapeutic paradigms, are frequently unavailable or constrained by a limited sample size and the heterogeneity of enrolled populations.

Given this context, therapeutic decisions are largely based on physicians’ experience, guidelines developed by expert panels, and extrapolations from available evidence derived from different disease settings.

This Special Issue is dedicated to small-cell lung cancer and rare thoracic tumors, with a particular focus on epithelial thymic tumors, thoracic neuroendocrine neoplasms, and pleural mesothelioma.

Through meticulously analyzed and thoughtfully contextualized perspectives, this edition of Current Oncology aims to provide readers with valuable insights and updates on the latest clinical research developments, helping them navigate the intricate landscape of therapeutic decision-making.

I look forward to receiving your contributions.

Prof. Dr. Tommaso Martino De Pas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.